Il linfoma di Hodgkin: evoluzione del trattamento dall’osservazione dei guariti

1. I tumori in Italia: rapporto AIRTUM 2012. Tumori infantili. Epidemiol Prev 2013;37(Suppl 1):1-296. 2. Küppers R. Clonotypic B cells in classic Hodgkin lymphoma. Blood 2009;114:3970-1. 3. Percy CL, Smith MA, Linet M. Lymphomas and reticuloendothelial neoplasms. In: Ries LA, Smith MA, Gurney JG, et al. (Eds). Cancer Incidence and Survival among Children and Adolescents: United States SEER Program, 1975-1995. National Cancer Institute, Bethesda, MD 1999, pag. 35. 4. Linet MS, Brown LM, Mbulaiteye SM, et al. International long-term trends and recent patterns in the incidence of leukemias and lymphomas among children and adolescents ages 0-19 years. Int J Cancer 2016;138(8):1862- 74. 5. Hjalgrim H, Askling J, Rostgaard K, et al. Characteristics of Hodgkin’s lymphoma after infectious mononucleosis. N Engl J Med 2003; 349(14):1324-32. 6. van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 2015;175:1007-17. 7. Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow- up project of the German-Austrian DALHD studies. Pediatr Blood Cancer 2010;55(6): 1145-52. 8. Steinherz LJ, Steinherz PG, Tan CTC, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672- 77. 9. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospectives analysis of the Childhood Cancer Survivors Study cohort. BMJ 2009;339: b4606. 10. Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from Childhood Cancer Survivors Study. Blood 2011;117:1806-16. 11. Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma. J Natl Compr Canc Netw 2015;13:554-86. 12. Venkatramani R, Kamath S, Wong K, et al. Pulmonary outcomes in patients with Hodgkin lymphoma treated with involved field radiation. Ped Blood Cancer 2014;61:1277-81. 13. Hancock SL, Cox RS, McDougall IR. Thyroid disease after treatment of Hodgkin’s disease. N Engl J Med 1991;325:599-605. 14. Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000;85:3227-32. 15. van Dorp W, van Beek RD, Laven JSE, et al. Long-term endocrine effects of childhood Hodgkin’s lymphoma treatment: a review. Hum Reprod Update 2012;18:12-28. 16. Veiga LH, Holmberg E, Anderson H, et al. Thyroid cancer after childhood exposure to external radiation: an updated pooled analysis of 12 studies. Radiat Res 2016;185:473-84. 17. Sieniawski M, Reineke T, Josting A, et al. Assessment of male fertility in patients with Hodgkin’s lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol 2008;19:1795-801. 18. Gerres L, Brämswig JH, Schlegel W, Jürgens H, Schellong G. The effects of etoposide on testicular function in boys treated for Hodgkin’s disease. Cancer 1998;83(10):2217-22. 19. Ben Arush MW, Solt I, Lightman A, Linn S, Kuten A. Male gonadal function in survivors of childhood Hodgkin and non-Hodgkin lymphoma. Pediatr Hematol Oncol 2000;17:239-45. 20. Viviani S, Ragni G, Santoro A, et al. Testicular dysfunction in Hodgkin’s disease before and after treatment. Eur J Cancer 1991;27: 1389-92. 21. Paoli D, Rizzo F, Fiore G, et al. Spermatogenesis in Hodgkin’s Lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens. Human Reprod 2016;31:263-72. 22. Pierik FH, Vreeburg JT, Stijnen T, de Jong FH, Weber RF. Serum inhibin B as a marker of Spermatogenesis. J Clin Endocrinol Metab 1998;83:3110-14. 23. Schellong G. Treatment of children and adolescents with Hodgkin’s disease: the experience of the German-Austrian Paediatric Study Group. Baillieres Clin Haematol 1996; 9:619-634. 24. van Beek RD, Smit M, van den Heuvel-Eibrink MM, et al. Inhibin B is superior to FSH as a serum marker for spermatogenesis in men treated for Hodgkin’s lymphoma with chemotherapy during childhood. Hum Reprod 2007a;22:3215-22. 25. Green DM, Sklar CA, Boice JD, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 2009b;27:2374-81. 26. Lie Fong S, Laven JS, Hakvoot-Cammel FG, et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti- Mullerian hormone. Hum Reprod 2009;29:982- 90. 27. Van Disseldorp J, Lambalk CB, Kwee J, et al. Comparison of inter and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod 2010;25:221-7. 28. Sklar CA, Mertens AC, Mitby P, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006;98:890-6. 29. De Bruin ML, Huisbrink J, Hauptmann M, et al. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood 2008;111:101-8. 30. Wallace WHB, Thomson AB, Kelsey TW. The radiosensivity of the human oocyte. Hum Reprod 2003;18:117-121. 31. Redman JR, Bajorunas DR, Wong G, et al. Bone mineralization in women following successful treatment of Hodgkin’s disease. Am J Med 1988;85:65-72. 32. Grumbach MM. Estrogen, bone, growth and sex: a sea change in conventional wisdom. J Pediatr Endocrinol Metab 2000;13(Suppl. 6):1439-55. 33. Boot AM, Nauta G, de Jong MC, et al. Bone mineral density, bone metabolism and body composition of children with chronic renal failure, with and without growth hormone treatment. Clin Endocrinol (Oxf) 1998;49:665-72. 34. van Beek RD, van den Heuvel-Eibrink MM, Hakvoort-Cammel FG, et al. Bone mineral density, growth and thyroid function in long-term survivors of paediatric Hodgkin’s lymphoma treated with chemotherapy only. J Clin Endocrinol Metab 2009;94:1904-09. 35. Sala A, Talsma D, Webber C, Posgate S, Atkinson S, Barr R. Bone mineral status after treatment of malignant lymphoma in childhood and adolescence. Eur J Cancer Care 2007;16:373-9. 36. de Vathaire F, El-Fayech C, Ben Ayed FF, et al. Radiation dose to the pancreas and risk of diabetes mellitus in childhood cancer survivors: a retrospective cohort study. Lancet Oncol 2012;13:1002-10. 37. van Nimwegen FA, Schaapveld M, Janus CP, et al. Risk of diabetes mellitus in long-term survivors of Hodgkin lymphoma. J Clin Oncol 2014;32:3257-63. 38. O’Brien MM, Donaldson SS, Balise RR Whittemore AS, Link MP. Second malignant neoplasms in survivors of pediatric Hodgkin’s lymphoma treated with low dose radiation and chemotherapy J Clin Oncol 2010;28:1232-9. 39. Schaapveld M, Aleman BM, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Eng J Med 2015;373:2499-511. 40. Eichenauer DA, Thielen I, Haverkamp H, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2014;123:1658-64. 41. Engert A, Diehl V, Franklin J, et al. Escalated- dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 stydy. J Clin Oncol 2009;27:4548-54. 42. Metayer C, Lynch CF, Clarke EA, et al. Second cancers among long-term survivors of Hodgkin’s disease diagnosed in childhood and adolescence. J Clin Oncol 2000;18: 2435-43. 43. Ibrahim EM, Abouelkhair KM, Kazkaz GA, Elmasri OA, Al-Foheidi M. Risk of second breast cancer in female Hodgkin’s lymphoma survivors: a meta-analysis. BMC Cancer 2012;12:197. 44. Dorffel W, Riepenhausen M, Luders H, Bramswig J, Schellong G. Secondary malignancies following treatment for Hodgkin’s lymphoma on childhood and adolescence - a cohort study with more than 30 years’ followup. Dtsch Arztebl Int 2015;112:320-7. 45. Green DM, Hyland A, Barcos MP, et al. Second malignant neoplasms after treatment for Hodgkin’s disease in childhood or adolescence. J Clin Oncol 2000;18(7):1492-9. 46. Mauz-Körholz C, Hasenclever D, Dörffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPACOPP in girls have comparable effectiveness in pediatric Hodgkin’s lymphoma: the GPOHHD- 2002 study. J Clin Oncol 2010;28(23):3680- 6. 47. Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 2009; 114(10):2051-9. 48. Kelly KM1, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high- risk Hodgkin lymphoma: a report from the Children’s Oncology Group. Blood 2011;117 (9):2596-603. 49. Burnelli R, Rinieri S, Todesco A, et al. Protocollo AIEOP-LH 2004 per la terapia del Linfoma di Hodgkin in età pediatrica: analisi ad interim. Haematologica 2008;93(Suppl 4): 27. 50. Greenlee RT, Hill-Harmon M, Murray T, Thun M. Cancer statistics 2001. CA Cancer J Clin 2001;51:15-36. 51. Schellong G. Treatment of children and adolescents with Hodgkin’s disease: the experience of the German-Austrian Paediatric Study Group. Baillieres Clin Haematol 1996;9 (3):619-34. 52. Vecchi V, Pileri S, Burnelli R, et al. Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients. Cancer 1993:15;72(6):2049-57. 53. Kung FH, Schwartz CL, Ferree CR, et al.; Children’s Oncology Group. POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children’s Oncology Group. J Pediatr Hematol Oncol 2006;28(6): 362-8 54. Robazza M, Mascarin M, Elia C, et al. Long-term results of the AIEOP MH-89 protocol for pediatric Hodgkin lymphoma. Oral communication, ESTRO 35, Torino, 2016. 55. Weiner MA, Leventhal B, Brecher ML, et al. Randomized study of intensive MOPPABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin’s disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol 1997;15(8):2769-79. 56. Oberlin O, Leverger G, Pacquement H, et al. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin’s disease: the experience of the French Society of Pediatric Oncology. J Clin Oncol 1992;10(10): 1602-8. 57. Donaldson SS, Link MP, Weinstein HJ, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin’s disease. J Clin Oncol 2007;25(3):332-7. 58. Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin’s disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 2000;18(7):1500-7. 59. Dörffel W, Rühl U, Lüders H, et al. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. J Clin Oncol 2013;31(12): 1562-8. 60. Wolden SL, Chen L, Kelly KM, et al. Longterm results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin’s lymphoma - a report from the Children’s Oncology Group. J Clin Oncol 2012;30(26):3174- 80. 61. Donaldson SS. A discourse, The 2002 Wataru W. Sutow Lecture: Hodgkin disease in children. Perspectivs and progress. Med Ped Oncol 2003;40:73-81. 62. Schwartz CL, Tebbi C, Constine LS, Mendenhall N, London WB, Chauvenet A. Response based therapy for pediatric Hodgkin’s disease (HD): Pediatric Oncology Group (POG) protocols 9425/9426. Med Ped Oncol 2001;37: 263. 63. Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29:1844-54. 64. Engert A, Haverkamp H, Kobe C, et al. Reduced- intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012;379:1791-9. 65. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of Imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014;32:3048-58. 66. Gallamini A, Barrington SF, Biggi A, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 2014;99:1107-13. 67. El-Galaly T, Mylam KJ, Brown P, et al. PET/CT surveillance in patients with Hodgkin lymphoma in first remission is associated with low positive predictive value and high costs. Haematologica 2012;97:931-6. 68. Portlock CS. Involved site radiation therapy for the treatment of early-stage Hodgkin lymphoma in adolescents and young adults. Clin Oncol Adolesc Young Adults 2015;5:97- 102. 69. Mascarin M, Giuliano FM, Coassin E, et al. Helical tomotherapy in children and adolescents: dosimetric comparisons, opportunities and issues. Cancer 2011;3:3972-90. 70. Scott LJ. Brentuximab vedotin: a review in CD30-positive Hodgkin lymphoma. Drugs 2017;77(4):435-45. 71. Ansell SM. Nivolumab in the treatment of Hodgkin lymphoma. Clin Cancer Res 2017;23 (7):1623-6. 72. Hude I, Sasse S, Engert A, Bröckelmann PJ. The emerging role of immune checkpoint inhibition in malignant lymphoma. Haematologica 2017;102(1):30-42.